KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other (2016 - 2020)

Regeneron Pharmaceuticals has reported Receivables - Other over the past 12 years, most recently at $460.8 million for Q3 2020.

  • Quarterly results put Receivables - Other at $460.8 million for Q3 2020, up 33.41% from a year ago — trailing twelve months through Sep 2020 was $460.8 million (up 33.41% YoY), and the annual figure for FY2019 was $260.6 million, up 15.11%.
  • Receivables - Other for Q3 2020 was $460.8 million at Regeneron Pharmaceuticals, up from $389.2 million in the prior quarter.
  • Over the last five years, Receivables - Other for REGN hit a ceiling of $468.3 million in Q1 2020 and a floor of $93.0 million in Q4 2016.
  • Median Receivables - Other over the past 5 years was $226.4 million (2018), compared with a mean of $249.8 million.
  • Biggest five-year swings in Receivables - Other: crashed 39.28% in 2016 and later skyrocketed 108.3% in 2017.
  • Regeneron Pharmaceuticals' Receivables - Other stood at $93.0 million in 2016, then skyrocketed by 108.3% to $193.7 million in 2017, then grew by 16.88% to $226.4 million in 2018, then grew by 15.11% to $260.6 million in 2019, then soared by 76.82% to $460.8 million in 2020.
  • The last three reported values for Receivables - Other were $460.8 million (Q3 2020), $389.2 million (Q2 2020), and $468.3 million (Q1 2020) per Business Quant data.